Background: Randomised controlled trials have demonstrated substantial clinical benefit for thrombectomy in patients with acute ischaemic stroke and proximal anterior circulation arterial occlusion.
Introduction
Recently, six positive randomised controlled trials (RCTs) of endovascular thrombectomy (TBY) for ischaemic stroke due to major anterior circulation vessel occlusion have provided strong evidence for substantially improved patient outcome compared with standard care including thrombolysis. [1] [2] [3] [4] [5] [6] Updated guidelines recommend TBY as a level 1 evidencebased treatment. [7] [8] [9] Implementation of system reorganisation that allows rapid delivery of TBY to all eligible patients is a challenge that currently is under development in many geographical areas and may require substantial investment of scarce resources. 10 Four earlier cost-effectiveness studies have extrapolated RCT-data and reported that TBY is likely a costeffective strategy. [11] [12] [13] [14] However, these analyses were restricted by lack of data on expected resource use beyond direct hospital costs. Ganesalingam et al. and Leppert et al. cited resource use during initial hospitalisation and prognoses for a re-current stroke as main cost drivers for their analyses. 12, 13 Aronsson et al. used Swedish resource use data on a general stroke population, which underestimates actual costs for patients with severe stroke. 11 Mangla et al. made within-study assumptions on need for home care (states 1-3 of the modified Rankin Scale, mRS) and care in a nursing home (mRS-states 4-5), but sensitivity analyses were not presented. 14 The RCTs on TBY had a follow-up period of three months for determination of effect on functional outcome and survival. However, functional status at three months (measured as modified Rankin scale, mRS) is also an important determinant for long-term survival. [15] [16] [17] For instance, Slot et al. estimated that the median length of survival was 9.7 years for those independent in daily living (mRS 0-2) compared to 6.0 years for those in dependent states (mRS [3] [4] [5] . In addition, the risk of recurrent stroke events may lead to further increase in degree of dependence. 18 Hence, in addition to the impact of the level of dependence after stroke, the cost effectiveness of TBY will be closely linked to its effect on survival.
We analysed the cost-effectiveness of TBY after thrombolysis compared to thrombolysis alone for patients with high probability of proximal arterial occlusion in the anterior cerebral circulation using a deterministic decision-analytic model developed in Microsoft Excel. The analyses adopted a broader societal perspective and used real-world outcome data on need for health care and social services for people with severe stroke from the Swedish Stroke Register (Riksstroke). The aim of the analyses was to include long-term resource use consequences of shifting the mRS-distribution towards less-dependent health states to consider the often permanent nature of increased dependence from a severe stroke. The article follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS). 19 
Methods

Population and subgroup analyses
To resemble the control group in the clinical trials, we selected patients with a severe ischaemic stroke defined as National Institutes of Health Stroke Scale NIHSS ! 8 before thrombolysis, treated with thrombolysis but not TBY, and with admission date from 1 January to 31 December 2014 in the Riksstroke database which has 96% coverage of incident stroke cases in Sweden. 20 Data on computed tomography (CT) angiography or vascular territory were not available. 21 Analyses were carried out for the average individual and stratified by age groups <65/65-74/75-84 years to mirror reported age distributions from trials as well as non-random variation in resource consequences from stroke. The average rate of thrombolysis in Sweden 2014 was 11.2%, whereas 1.3% of them were treated with TBY. 20
Study setting and perspective
The analyses had a societal perspective including resource use in health care, social services, and costs of lost production. For transparency, we report results as totals and by source in line with the Swedish health technology assessment guidelines. A particular challenge for decisions as regards the implementation of treatments of severe stroke is that short-term and long-term consequences of interventions are borne by different stakeholders. In the Swedish setting, costs of health care are mainly financed by flat rate income taxation at the regional level. However, long-term consequences including dependency due to reduced functional status are borne by the individual, family and the social service sector. Municipalities provide social services and are financed by another flat-rate income tax and by income-related fees paid by recipients.
Treatment strategies and time horizon
We modelled the long-term treatment effect from TBY merging data from the Riksstroke database and pooled mRS outcome data from 5 RCTs published in the New England Journal of Medicine 1,3-6 to obtain distributions at three months for intervention and control groups (Supplementary file, Table S2 ). 22 No weighting of study results was applied. The analysis had a societal perspective and 25-year time horizon. The base case analysis used 3% discount rate for costs and health outcomes following the Swedish guidelines. Discount rates of 0% and 5% were applied in sensitivity analyses. 1, 2, respectively, to Riksstroke data. Quality of life and survival was linked to mRS-states in the model analysis (see below). Health utilities were obtained from the literature (Rivero-Arias, 23 Table 3 , p.348) as the clinical trials did not report quality-of-life data by mRSstates. 23 Sensitivity analyses explored results of alternative utility sets (Table 1) . 12, 13, 24 The impact on quality of life on spouse or significant other was not included due to lack of data.
Resource use and unit costs
To reflect real-world practice, we obtained age-stratified resource use data by mRS-status at three months from the Riksstroke. Standard care was assumed to include thrombolysis and to be equivalent between the two treatment arms except for the TBY costs. Resource use for TBY was anchored in detailed actual resource use data from Ska˚ne University Hospital records for 10 patients treated with TBY between January and September 2015. Resource use for the post-acute phase care, rehabilitation, as well as subsequent need for home-help services and nursing home care was linked to mRS and data obtained from Riksstroke (Table1; Supplementary file, Table S3 ).
Riksstroke reports the proportion of patients admitted to nursing home care at three months. We assumed that patients who had been admitted to a nursing home would remain nursing-home residents for the rest of their lives. Assumptions were made for the need of home-help services based on reports from the Swedish national health data registers for people with stroke 25 and the Swedish National Board of Health and Welfare. 26 From Riksstroke, we retrieved annual survival data totally and by mRS at three months for all cases registered from 2007 to 2009 with International Classification of Diseases version 10 diagnosis I63. The mRS score was derived according to Eriksson et al. 27 and reported by mRS 0-2, 3, 4, 5, and 6 (dead) (see Supplementary material for details). We applied conservative assumptions for loss of production ( Table 2 ; see Supplementary material for description including Table S1 ).
All costs used year 2015 prices in Swedish Krona (SEK) and converted to British Pounds (GBP) using average annual exchange rate for January-December 2015 from the Swedish central bank (www.riksbank.se GBP 1 ¼ SEK 12.8962).
Model design
To capture the long-term consequences for resource use and patient benefits of shifting the distribution of mRS at three months, we developed a decision-analytic model which incorporates the need for long-term community care and nursing home residency ( Figure 1) . Patients entered the model at stroke onset where they received either TBY þ thrombolysis or thrombolysis alone as the standard care. The short-run decision-analytic cohort model distributed patients across seven possible mRS health states at three months after initial stroke (mRS 0-6).
A long-run Markov state transition cohort model was then used to estimate the costs and outcomes in a 25-year perspective using one-year cycles. Figure 1 illustrates the model structure where at the end of each cycle, patients either remained in their current health state, died, or had a recurrent stroke which would increase dependence as measured by mRS. In Figure 1 , the long-run model is expanded for mRS 0 to show the assumptions on possible consequences of recurrent stroke. The base case analysis assumed a uniform distribution on more severe mRS-states after a recurrent stroke. Other distributions were explored in the sensitivity analyses (see Supplementary material model description).
Results
Real-world data on days of hospitalisation, rehabilitation interventions, and nursing home residency was retrieved from Riksstroke for a population selected to match the clinical trial study groups. In total, 710 patients registered in Riksstroke with a severe ischaemic stroke (NIHSS ! 8 before thrombolysis, median 14) were treated with thrombolysis but not TBY in 2014 in Sweden. mRS-status at three months after index stroke was available for 541 patients (76%) of which 88 were deceased. Resource use data by age group <65/65-74/75-84 years and mRS-status are given in the Supplementary material, Table S3 . In general, days of hospitalisation increased with age and mRS-score with the exception of the eldest age group and patients with mRS 4 and mRS 5. In these groups, the percentage of patients discharged to nursing home residency was high (65-74 years mRS 4 25%, mRS 5 89%; 75-84 years mRS 4 41%, mRS 5 88%; see Supplementary files, Figure S1 ). In addition, patients discharged to their own home received increased home-help services in the year after the initial stroke: 7%/78%/80%/88% by mRS 0-2/3/4/5 (Sveus 25 and personal communication I Lekander).
Five-year survival rates by age group after an index ischaemic stroke by mRS-status in Riksstroke 2007-2009 (n ¼ 33,566) are shown in Figure 2 . Dependent mRS-states imply higher mortality in all three age groups, and overall mortality was higher for the older age groups as expected. At three months, 20% International Journal of Stroke, 12(8) . Model structure. Decision tree structure of clinical trial outcome by modified Rankin scale, mRS, at three months followed by the long-term Markov model including six health states characterized by mRS, one health state for recurrent stroke, and death. Here illustration of consequence of recurrent stroke for patient in mRS 0 at three months with an annual probability of a recurrent stroke, death or unchanged mRS. International Journal of Stroke, 12 (8) give additional analyses of survival after an index ischaemic stroke in Riksstroke data. Table 2 shows the model-predicted average longterm costs and health gain results per patient for TBY and standard care with thrombolysis alone. Age group-specific results were weighted by size of age groups (22%/31%/47%) in the Riksstroke year 2014 cohort of people with severe stroke (see above). Providing TBY implies a net increase in costs in the hospital phase by about GBP 9000 even if the shift towards less-dependent mRS-states also reduces hospital length of stay based on mRS-outcomes from published clinical trials (see Supplementary material, Table  S2 ). Nevertheless, a bigger impact is expected on costs in the social services sector including home help services and nursing home residency. The weighted average reduction in costs of social services alone is about GBP 39,000.
The results in Table 2 are driven by the finding from clinical trials where the proportion of patients ending up with mRS 4 or mRS 5 at three months was reduced from 38% in the control group with standard care to 21% in the intervention group receiving TBY (Figure 2 ; Supplementary material Table S3 ; Figure S1 ). From the societal perspective, including hospital care costs, social services costs, and for people in active ages (<65 years) also costs of lost production, TBY would in the 25-year perspective be both cost-saving (net-savings corresponding to GBP -35 000) and improve patient benefits (þ0.45 life year; þ1.02 quality-adjusted life year, QALY). Although not cost-saving with the restricted hospital care perspective, the estimated incremental cost-effectiveness ratio (ICER) was estimated to be below GBP 10,000. Figure 3 shows the results of the differences in costs (panel a) and health gains as measured by added life Figure 2 , a non-favourable outcome after a severe stroke in the youngest age group is likely to be associated with many years of need for social services including costly nursing home residency.
Sixteen one-way sensitivity analyses explored the impact on costs and health gains from the assumptions made in the model analysis in the societal and the more restricted perspectives (see Supplementary material, Table S4 ). TBY was always found to be cost-saving in the societal perspective and when including costs of social services. Reducing the model time horizon from 25 to 5 years had the greatest impact on results reducing expected total cost-savings from about GBP 35,000 to about GBP 17,000. Differences in health gains were also reduced (þ0.12 life year, þ0.44 QALY), but the incremental cost-effectiveness ratio in the restricted hospital care perspective was below GBP 21,000, and considering costs of social services would still imply that TBY would be considered a dominant strategy (cost-saving and yielding health gains).
Discussion
Our study is the first to convincingly demonstrate that the predicted need for home-help services and nursing home residency for the dependent mRS-state is likely to make TBY a cost-saving intervention in the societal perspective under all reasonable scenarios and also with a five-year time-horizon. Although a substantial part of patients will experience reduced function in activities of daily living (ADLs) with both treatment alternatives, the shift in dependency distribution shown by five RCTs published during 2015 will reduce the burden of stroke in such a way that the cost-offset in the longer term will more than compensate for the more expensive TBY during initial hospital care. These results were robust in all sensitivity analyses and TBY was always cost-saving when considering costs of social services including home help and nursing home care.
While previous cost-effectiveness analyses [11] [12] [13] [14] were forced to disregard, or make assumptions on need for social services to be attributed to each mRS-status from broad stroke-patient populations or expert opinion, this study relies on actual estimates from a national sample of the patient sub-group where TBY is a relevant treatment alternative. Notably, previous costeffectiveness analyses assumed rather low long-term costs of social services in dependent mRS-states. For instance, Ganesalingam et al. applied an on-going cost of US Dollar (USD) 2075 every three months for mRS 3-5 which amounts to less than USD 10,000 per year. 12 The study by Leppert et al. assumed annual long-term costs of USD 17,704 for mRS 4-5. 13 The other Swedish study 11 made assumptions based on data from an unselected stroke population and applied an annual cost estimate corresponding to GBP 4600 for mRS 4-5. The data on resource use from Riksstroke show a strong association between estimated degree of dependence by mRS-score and the distribution of people able to remain in their own home vs. needing nursing home care. In the subsample of people with NIHSS !8 and thrombolysis treatment in Riksstroke from year 2014, 31%/86% of people with mRS 4/5 at three months post initial stroke were living in a nursing home compared to 15% for mRS 3. One-year residency in a nursing home is estimated to cost about GBP 50,000. Thus, the expected annual cost for nursing home care in for example mRS 5 is likely to exceed GBP 40,000 considering the high probability. In addition, people living at home are eligible for home-help services and our model assumptions are supported by recent national real-world data from Sweden (Sveus, 25 and personal communication I Lekander).
Two main strengths of our study are that it is based on real-world data on resource use by mRS, especially from the social services sector, and that modelling of patient benefits allowed differentiation between dependent mRS-states. Our data emphasise that crucial benefits of TBY are found among patients worst off when avoiding mRS 4 or 5.
However, several limitations should be recognised. (a) Details on vascular territory, and findings and timing of CT angiography are not recorded in Riksstroke. Presence of anterior circulation large artery occlusion was not proven in our study cohort from Riksstroke. However, the majority of all strokes (>80 %) occur in the anterior circulation. Using a NIHSS score cut-off of !8 has a likelihood of >80% of a large artery occlusion being present on vascular imaging. 21, 28 However, studies have shown that cutoff scores are time dependent, and are not fully precise for use in clinical practice to triage patients potentially suitable for TBY. [29] [30] [31] (b) Another limitation was that Riksstroke report grouped results for independent mRS-states 0-2. The model distinguishes between all single mRS-states, but for survival and resource use, the same figures were used for mRS 0 to mRS 2. In principle, this will probably underestimate survival for mRS 0 as well as overestimate costs, but to some extent International Journal of Stroke, 12 (8) overestimate survival for mRS 2 and underestimate costs. However, as shown in the sensitivity analyses, applying individual level survival also for independent mRS-states based on published results from the UK 15 only marginally changed the longer-term costs and health gains.
Three further limitations are: (c) the assumption that the mRS-status at three months is a reasonable predictor for the longer-term stroke-related health and social care needs. Although the model allowed a progression of the disease towards increased dependence as measured by mRS through the occurrence of re-stroke, the model did not allow improvement in mRS over time. However, the assumption made in this study is in line with previous studies and seems to be a reasonable assumption especially for the older age groups. The lack of longer-term follow-up data makes model simulation and collating data from multiple sources a suitable strategy to elucidate expected costs and health gains over time. (d) The results presented are based on expected marginal costs of resources used in the treatment chain in the provision of stroke care, but do not include transition costs related to structural change and the implementation of TBY as a new treatment alternative. Such costs may include extra costs of specialist education and reorganisation of acute care and stroke unit care; and finally (e) that the analysis lacked data on the size of the burden on informal caregivers including loss of quality of life.
Seen from a broader societal perspective, social services costs are important in health economic analyses of the burden of stroke and for guiding health policy decisions with respect to interventions in stroke care. This is especially relevant in cases of severe stroke where half of patients may end up with mRS health states 3-5 also when treated with today's standard care with thrombolysis. In the Swedish setting, the main burden of social services costs will fall on municipalities financed by a proportional income taxation and some government subsidies. Households also bear part of the burden through income-related fees for social services charged by municipalities. Total fees paid by recipients cannot exceed costs of the service and the individual is guaranteed monthly amount for living costs (about GBP 400). In other institutional settings, limited access to publicly financed social services will place both care and financial burden on households which may lead to economic difficulties for the patient and his/her family over time.
The detailed presentation of data including Supplementary material is provided to support analyses conducted in other settings and health care systems. Although we expect differences in organisational structures between countries as well as different unit costs of services, the expected consequences of treatment alternatives and mRS-related outcomes on need for social services and survival provide new unique insights to the burden of stroke in the long-term perspective. This study confirms previous positive cost-effectiveness assessments of TBY but also emphasises the importance of looking beyond hospital discharge when understanding the value of new treatments.
